TSZY(SZ:002872)2025-09-25 09:22Group 1: Financial Status and Challenges - The company is currently in a loss situation due to the impact of the domestic and international economic downturn, as well as adjustments in the pharmaceutical industry [3] - As of April 8, 2021, the principal and interest of funds occupied by the controlling shareholder have been fully repaid [2] - The company received an administrative penalty notice from the Chongqing Securities Regulatory Bureau on September 12, 2025, leading to additional risk warnings on stock trading from September 15, 2025 [2] Group 2: Strategic Measures and Future Plans - The company aims to achieve profitability by focusing on "deep research, precise production, and expanded sales" to adapt to industry trends and seize opportunities for sustainable development [3] - The sales expenses account for over 20% of revenue due to the need to establish a nationwide sales network for distributing quality pharmaceuticals [3] - The company is considering share repurchase plans to enhance investor confidence and maintain market value, depending on market conditions and funding availability [6] Group 3: Governance and Compliance - The company is committed to strengthening corporate governance and improving internal control management to address compliance issues [4] - There are plans to disclose any future mergers, acquisitions, or divestitures in accordance with regulatory requirements [5] Group 4: Product Development and Quality Assurance - The company has over 300 approved drug varieties covering multiple therapeutic areas, including pediatrics, respiratory, gynecology, cardiovascular, digestive, orthopedic, and anti-infection treatments [5] - The company adheres to strict quality control standards, producing products in compliance with GMP regulations, although it currently does not engage in pharmaceutical exports [5]